COMMUNIQUÉS West-GlobeNewswire

Alfasigma Announces New Linerixibat Data Across PBC and Liver Disease to be Presented at AASLD’s The Liver Meeting 2026
02/11/2026
Five presentations will highlight new analyses of linerixibat in cholestatic pruritus associated with primary biliary cholangitis, including an oral presentation and four posters from the Phase 3 GLISTEN study and real- [...]
CytomX Therapeutics to Present at Upcoming November Investor Conferences
02/11/2026
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will [...]
Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Tuesday, November 10, 2026
02/11/2026
FLORHAM PARK, N.J., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of [...]
CRISPR Therapeutics Announces the Appointment of Siva Sakhamuri, Ph.D., as Chief Technical Officer
02/11/2026
ZUG, Switzerland and BOSTON, Nov. 02, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), today announced the appointment of Sivakesava (Siva) Sakhamuri, Ph.D., as Chief Technical Officer, effective immediately [...]
New Data Presented at AHA Scientific Sessions 2026 Demonstrate That CARDAMYST® (etripamil) Nasal Spray Converted Recurrent PSVT to Normal Heart Rhythm in Patients with Prior Catheter Ablation
02/11/2026
MONTREAL and CHARLOTTE, N.C., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular [...]
Eyconis to Participate in Upcoming Investor Conferences
02/11/2026
REDWOOD CITY, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Eyconis, Inc., a clinical-stage biotechnology company advancing next-generation, long-acting ophthalmic therapeutics, today announced that members of its [...]
Humacyte To Announce 2026 Third Quarter Financial Results and Provide Business Update on November 10, 2026
02/11/2026
DURHAM, N.C, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today [...]
Theriva™ Biologics Announces Sale of SYN-004 (ribaxamase) and Related Antibiotic-Degrading Enzyme Portfolio to Biossil Labs Inc.
02/11/2026
– Theriva received a $350,000 upfront payment at closing and is eligible for up to $91 million in regulatory and sales milestones, along with low single-digit royalties on net product sales – – Biossil to assume all [...]
Rein Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference
02/11/2026
AUSTIN, Texas, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines in orphan pulmonary and fibrosis indications [...]
Enlivex Announces Favorable 12-Month Topline Data from Phase I/IIa Allocetra Trial, Demonstrating Durable Treatment Response
02/11/2026
In patients aged 64+: 79.2% of patients achieved a clinically meaningful response (reduced pain and improved knee function) in the Allocetra™ group vs. 47.6% in the placebo group at 12 months (p=0.027) 1 Allocetra™ [...]
Lyell Immunopharma To Participate in November Investor Events
02/11/2026
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell [...]
Chemomab Therapeutics and Scipher Medicine Announce SEC Registration Statement on Form S-4 Is Effective
02/11/2026
Special meeting of Chemomab shareholders to vote on the proposed merger scheduled for December 4, 2026 TEL AVIV, Israel, and DURHAM, N.C., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Chemomab Therapeutics (Nasdaq: CMMB) (“ [...]
Vera Therapeutics to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
02/11/2026
BRISBANE, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced that the Company’s management team will participate in a fireside [...]
Teva to Discontinue Phase 2 TOPAS-MSA Study of emrusolmin (TEV-‘286) Following Interim Futility Analysis
02/11/2026
Predictive Interim analysis indicates low probability of study meeting its primary efficacy endpoint if continued Comprehensive analysis and evaluation of available open-label extension data will follow No safety [...]
Sionna Therapeutics to Participate in Upcoming November 2026 Investor Conferences
02/11/2026
WALTHAM, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to develop novel medicines for cystic fibrosis (CF), today announced [...]
A3P Biomedical appoints Matt Franklin as President, North America to accelerate US market access for Stockholm3
02/11/2026
STOCKHOLM, Nov. 02, 2026 (GLOBE NEWSWIRE) -- A3P Biomedical AB (publ), a Swedish company specializing in advanced prostate cancer screening, today announces the appointment of Matt Franklin as President of A3P [...]
Radiopharm Theranostics Reports Business Update
02/11/2026
Phase 3 imaging trial of RAD101 in recurrent brain metastases from solid tumors expected to initiate in 1Q27 following successful end-of-phase 2 meeting with U.S. Food and Drug Administration Reported positive Phase 1 [...]
Actuate Therapeutics Receives U.S. Notice of Allowance for Patent Covering Elraglusib Oral Tablets
02/11/2026
Oral tablet form expected to allow Company to optimize patient plasma exposure levels with convenient daily dosing of drug Sustained plasma levels of elraglusib expected to have multiple effects on immune cell dynamics [...]
UroGen Announces First Patient Dosed in Phase 1 Trial of UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer
02/11/2026
Phase 1 clinical trial to evaluate local intravesical administration of UGN-501 UGN-501 is a differentiated investigational next-generation oncolytic virus designed to combine direct tumor cell destruction with anti- [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum